Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck (Q28347912)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

title

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

head and neck squamous cell carcinoma

10 November 2019

main subject

1 reference

metastatic squamous cell carcinoma

inferred from title

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Raymond E

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Laguerre B

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Degardin M

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Cals L

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Armand JP

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Lefebvre JL

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Gedouin D

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Ripoche V

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Kayitalire L

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Niyikiza C

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Johnson R

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Latz J

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Schneider M

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

language of work or name

English

0 references

publication date

1 September 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

10 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

649-655

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

10 November 2019

start time

1 August 2001

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Overview of phase II trials of MTA in solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364119

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364119

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364119

Overview of MTA in the treatment of non-small cell lung cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364119

29 September 2017

Cancer statistics, 1999.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364119

Clinical studies with MTA.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364119

Overview of combined modality therapies for head and neck cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364119

Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Gro

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364119

A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. A Northern California Oncology Group study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364119

The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364119

Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364119

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364119

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

2 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1054%2FBJOC.2001.2010

Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells

21 January 2018

1 reference

12 December 2020

A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer

1 reference

12 December 2020

1 reference

12 December 2020

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid

1 reference

12 December 2020

Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid

1 reference

12 December 2020

The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol

1 reference

12 December 2020

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.2001.2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

10 November 2019

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

PubMed publication ID

11531245

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11531245%20AND%20SRC:MED&resulttype=core&format=json